Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Tuscano

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell LymphomaJulio C Chavez, Francine M Foss, Basem M William, et al.
The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Pageof 7